Cargando…
The Vitamin D Receptor Agonist BXL-01-0029 as a Potential New Pharmacological Tool for the Treatment of Inflammatory Myopathies
OBJECTIVE: This study aims to investigate in vitro the effect of the VDR agonist BXL-01-0029 onto IFNγ/TNFα-induced CXCL10 secretion by human skeletal muscle cells compared to elocalcitol (VDR agonist), methylprednisolone, methotrexate, cyclosporin A, infliximab and leflunomide; to assess in vivo ci...
Autores principales: | Di Luigi, Luigi, Sottili, Mariangela, Antinozzi, Cristina, Vannelli, Gabriella Barbara, Romanelli, Francesco, Riccieri, Valeria, Valesini, Guido, Lenzi, Andrea, Crescioli, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813757/ https://www.ncbi.nlm.nih.gov/pubmed/24204948 http://dx.doi.org/10.1371/journal.pone.0077745 |
Ejemplares similares
-
Association of circulating CXCL10 and CXCL11 with systemic sclerosis
por: Crescioli, Clara, et al.
Publicado: (2018) -
EHMTI-0029. Medicated headache mask
por: Hyson, M
Publicado: (2014) -
The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis
por: Colasanti, Tania, et al.
Publicado: (2022) -
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition
por: Corinaldesi, Clarissa, et al.
Publicado: (2021) -
Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells
por: Antinozzi, C., et al.
Publicado: (2017)